QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.
List of Figures
Figure 55: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 56: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26